NCT04452591 2026-03-16
BOND-003
CG Oncology, Inc.
Phase 3 Active not recruiting
Clinical Trials
5 trialsNCT06443944 2026-03-06
An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
CG Oncology, Inc.
Available
NCT07283835 2026-01-21
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Lepu Biopharma Co., Ltd.
Phase 2 Recruiting
NCT06111235 2026-01-12
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
CG Oncology, Inc.
Phase 3 Active not recruiting
NCT04387461 2024-09-25
CORE-001
CG Oncology, Inc.
Phase 2 Completed